Showing 421-430 of 3173 results for "".
- LEO Foundation Plans to Double Philanthropic Grants for Skin Diseaseshttps://practicaldermatology.com/news/leo-foundation-plans-double-philanthropic-grants-skin-diseases/2462483/Reporting a successful year in 2023, the LEO Foundation has announced its goals and aspirations out to 2030, including the awarding of a prestigious 5 million Danish kroner prize to a distinguished researcher in Denmark contributing to skin research. The Foundation plans to double its philanthropic…
- Probiotics Top List of Acne Supplement Ingredientshttps://practicaldermatology.com/news/probiotics-top-list-acne-supplement-ingredients/2462477/The most popular dietary supplements for acne contain probiotics, diindolylmethane, vitamin A, vitamin B complex, and zinc, according to a review of 13 supplements. Although surveys have shown that many acne patients opt for dietary supplements as adjunctive treatments, these products are not subje…
- Galderma Prices IPO; Will Start Trading on the Swiss Stock Exchange Todayhttps://practicaldermatology.com/news/galderma-prices-ipo-will-start-trading-on-the-swiss-stock-exchange-today/2462444/Dermatology leader Galderma Group announced the pricing of its initial public offering at CHF 53 ($59) per share in Switzerland. The shares will be listed and start trading under the ticker symbol “GALD” on the SIX Swiss Exchange, on March 22, 2024. At the recent American Academy of Dermatology As…
- American Acne and Rosacea Society (AARS) Now Accepting Research Grant Award Applicationshttps://practicaldermatology.com/news/the-american-acne-and-rosacea-society-aars-is-now-accepting-applications-for-research-grant-awards/2462440/The American Acne and Rosacea Society (AARS) has announced the commencement of its grant application cycle for AARS Clinical Research Awards ($10K) and the prestigious AARS Research Scholar Award ($75K). According to a press release, the AARS offers its Clinical Research Awards for the advancement…
- Shaperon Enrolls First Patient in Phase 2 Clinical Trial for Atopic Dermatitis Therapy 'Nugel'https://practicaldermatology.com/news/shaperon-enrolls-first-patient-in-phase-2-clinical-trial-for-atopic-dermatitis-therapy-nugel/2462439/Shaperon announced the enrollment of the first patient in the phase 2 clinical trial for atopic dermatitis treatment candidate Nugel. The trial will evaluate the efficacy of Nugel in improving the Eczema Area Severity Index (EASI) across a cohort of 210 patients with mild to moderate atopic dermat…
- New Data on Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in ADhttps://practicaldermatology.com/news/new-data-on-long-term-efficacy-of-nemolizumab-in-prurigo-nodularis-and-its-durability-in-ad-1/2462433/Galderma announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.[1] Additionally, data from the ARCADIA 1 and 2 trials in atopic dermatitis indicate that the majority of pat…
- LEO Pharma Presents New Long-Term Adbry (Tralokinumab-ldrm) Data in Adults with Moderate-to-Severe ADhttps://practicaldermatology.com/news/leo-pharma-presents-new-long-term-adbry-tralokinumab-ldrm-data-in-adults-with-moderate-to-severe-ad/2462432/LEO Pharma unveiled new data analyzing the long-term therapeutic response of treatment with Adbry (tralokinumab-ldrm) in adults with moderate-to-severe atopic dermatitis (AD). The findings were shared via an e-poster at the 82nd American Academy of Dermatology (AAD) Congress in San Diego.[1] “The …
- INTEGUMENT-PED: Roflumilast Cream 0.05% Effective at Improving AD in Childrenhttps://practicaldermatology.com/news/integument-ped-roflumilast-cream-005-effective-at-improving-ad-in-children/2462429/New data from a pivotal phase 3 trial indicates roflumilast cream 0.05% is associated with significantly improved atopic dermatitis (AD) in children 2 to 5 years of age with mild-to-moderate AD. Researchers for the Interventional Trial Evaluating Roflumilast Cream for the Treatment of Atopic Dermat…
- Lebrikizumab Linked with Improvement in Patients with AD and Skin of Colorhttps://practicaldermatology.com/news/lebrikizumab-linked-with-improvement-in-patients-with-atopic-dermatitis-and-skin-of-color/2462431/New first-of-its-kind research presented at the American Academy of Dermatology 2024 Annual Meeting suggests that lebrikizumab showed efficacy in patients with skin of color who had atopic dermatitis (AD). “People with skin of color are disproportionately affected by AD, often experiencing more se…
- Study: Seborrheic Dermatitis Has Distinct Molecular Signaturehttps://practicaldermatology.com/news/study-seborrheic-dermatitis-has-distinct-molecular-signature/2462428/Newly unveiled research suggests that seborrheic dermatitis has its own unique molecular signature and is distinct in its own disease-specific pattern. “The pathophysiology of seborrheic dermatitis has been poorly understood. We sought to understand the gene expression patterns in seborrheic dermat…